Oura Postpones $15 Billion Stock Market Listing Amid Market Uncertainty

Oura, the company behind the health-tracking smart ring, has withdrawn its plans for a stock market listing that would have valued the firm at $15 billion. The announcement comes just days after the company officially filed documents to raise up to $2.2 billion through an initial public offering (IPO) on the Nasdaq stock market index.

Citing "uncertainty in the Initial Public Offering (IPO) market," Oura stated it would postpone its flotation without specifying a new timeline. This move makes Oura the latest business to delay its public debut as the IPO market becomes increasingly difficult.

Earlier this month, U.S. nuclear technology firm Holtec International also postponed its own stock market listing, attributing the decision to an "unusual confluence of developments that has impaired investor confidence." Factors contributing to this market sentiment include rising energy costs, global military conflicts, trade tensions, and inflation concerns, which have prompted central banks, including the U.S. Federal Reserve, to increase benchmark interest rates. The yield on 10-year U.S. debt recently reached its highest level since 2007.

Oura's chief executive, Tom Hale, acknowledged the challenging market, stating that "an IPO is just one step in our journey," and that the company has "the luxury of choosing our moment."

In its last full fiscal year ending September 30, 2025, Oura reported a pre-tax profit of $23.5 million on sales of $907.8 million, an increase from the previous year's $6.2 million pre-tax profit. For the nine months ending June 30 of this year, the company generated $70 million in pre-tax income on sales totaling $1.2 billion.

Founded in Finland in 2013, Oura has its global headquarters in San Francisco. Its smart rings, priced at over $300, monitor physiological signals such as heart rate, heart rate variability, movement, breathing patterns, and temperature to track sleep and other health metrics, which are then analyzed and presented on a companion app.

The company is currently facing a class action lawsuit that accuses Oura of false advertising regarding its ability to accurately measure sleep activity and patterns. The lawsuit, filed in August, contends that Oura rings cannot measure sleep because it is a brain-related activity. Oura has stated it "stand[s] behind our science, research and accuracy claims," adding that its ring estimates sleep stages using multiple physiological signals.

It is understood that Oura's decision to delay its IPO is not connected to the ongoing lawsuit.